Foresight Institute Radio cover image

Nir Barzilai | Targeting Aging with Metformin

Foresight Institute Radio

00:00

Metformin Is a Tool to Target Aging and Delay Aging

The DPP trial took non diabetic people and gave them metformin and showed a 30% decrease in the rate of diabetes over four years. Another intervention study was the UKT PDS, where it showed that midforming, unlike insulin or other drugs, sulfonyl or ria other drugs, the Chris cardiovascular disease by 36%. And overall mortality by 36%. Next, their association studies are not as good as as intervention studies. But if you have 200 of them, and there are more that are all showing, you know, when you're in midformin you have less cancers, and it's all cause of cancer. Because of those reasons we use metformin as a

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app